Copanlisib Chinese PK Study

Status Completed

Clinical Trial Summary

This study will be conducted primarily to determine the pharmacokinetics of copanlisib in Chinese patients with relapsed iNHL. The primary objective of the study is to determine the pharmacokinetics of copanlisib administered on Day1, 8, and 15 of a 28-days cycle (3 weeks-on/1 week off dosing regimen) as a 1 hour intravenous infusion to Chinese patients with relapsed iNHL. The secondary objectives include the evaluation of safety, tolerability, and tumor response of Chinese patients treated with Copanlisib. Determine the pharmacokinetics of M-1 metabolite.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03498430
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 1
Start date	April 27, 2018
Completion date	June 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05540340` - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant	Phase 1
Recruiting	`NCT04460235` - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma	Phase 4
Completed	`NCT03484702` - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 2
Completed	`NCT01410630` - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Completed	`NCT06190457` - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed	`NCT02369016` - Phase III Copanlisib in Rituximab-refractory iNHL	Phase 3
Recruiting	`NCT01676805` - Tissue Collection for Studies of Lymph Cancer
Terminated	`NCT00916045` - Pilot Study of Unrelated Cord Blood Transplantation	Phase 2
Completed	`NCT00534989` - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT	N/A
Terminated	`NCT00529503` - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL	Phase 2
Withdrawn	`NCT00538096` - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma	Phase 1
Completed	`NCT00156013` - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)	Phase 1/Phase 2
Withdrawn	`NCT00319332` - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen	Phase 3
Completed	`NCT00322842` - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients	Phase 2
Completed	`NCT00141297` - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer	Phase 1
Completed	`NCT02509039` - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)	Phase 1
Completed	`NCT00268203` - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT01573000` - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)	Phase 2
Completed	`NCT03289182` - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)